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Synovial sarcoma accounts for 5–10% (Choong et al, 1994) of all
soft tissue sarcomas and occurs most often in adolescents and
young adults (Cadman et al, 1965). A tumour-specific trans-
location t(X;18) (p11.2;q11.2) (SYT/SSX) (Limon et al, 1991), is
represented in more than 95% of the cases. Almost all synovial
sarcomas are histopathologically classified high-grade lesions.
The reported 5-year overall survival rate varies from 40 to 70%
(Wright et al, 1982; Choong et al, 1995). Besides tumour size,
which has been shown to be associated with poor clinical outcome
(Hajdu et al, 1977; Brodsky et al, 1992; Skytting et al, submitted),
there are few objective markers predicting the prognosis of this
malignant disease.
The p53 gene, a tumour suppressor gene, is believed to play an
active role in the cell growth control (Raycroft et al, 1990) by
acting as a regulatory checkpoint in the cell cycle, arresting the
cells in G1 phase if DNA damage has occurred (Yin et al, 1992). In
contrast, mutated p53 fails to block cell cycle progression (Nigro
et al, 1989). Therefore, p53 mutations may contribute to uncon-
trolled cell growth. Point mutation of mis-sense type produce a
product with a considerable longer half-life compared to germline
p53, leading to accumulation of defect p53 protein in the nucleus,
that can be assayed by immunohistochemistry (Finlay et al, 1988).
However, the significance of p53 immunostaining is controversial
since false negative detection due to e.g. nonsense-, frame-shift-,
splize mutations, or gross deletions (Wadayama et al, 1993) and
false positive detection due to stabilization of wild-type p53 by
e.g. Mdm2 or DNA damage in cells (Cordon-Cardo et al, 1994),
exists. Nevertheless, association between positive p53 immuno-
staining and impaired clinical course has been reported (Drobnjak
et al, 1994; Kawai et al, 1994; Wurl et al, 1997).
Ki-67 is an antigen exclusively expressed during the prolifer-
ating phase of the cell cycle (Gerdes et al, 1984). The function of
Ki-67 is still unknown, but it is a well established marker for
proliferation. Since MIB-1 index recognizes all phases of the cell
cycle (not in G0) it is a considerably more sensitive proliferation
marker than mitotic index.
The prognostic significance in soft tissue sarcomas (STS)
regarding both these markers remains unclear, mainly due to small
or heterogeneous materials. Patients with high/low tumour grades,
primary/recurrent tumours, various tumour sites (retroperitoneal
mixed with extremities) and different soft tissue entities have been
included in the same materials with a variety of results. In a recent
study concerning primary high-grade mixed STS, Ki-67 was
shown to be an independent prognostic marker (Heslin et al, 1998)
but in a material with malignant fibrous histiocytomas it was not
(Zehr et al, 1990). In a large material of mixed STS, over-expres-
sion of p53 was associated with reduced survival (Drobnjak et al,
1994) but in another large study of mixed STS this was not
confirmed (Nakanishi et al, 1997). So far neither MIB-1 nor p53
has been assessed for a large number of synovial sarcoma patients.
The purpose of this study was to analyse the prognostic impor-
tance of proliferation index, measured by the MIB-1 monoclonal
antibody, and the expression of p53 in a large material of clinically
and histopathologically well-characterized synovial sarcoma
patients.
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Summary In a study based on formalin-fixed paraffin-embedded material from 86 patients with primary synovial sarcoma located in the
extremities or on the trunk wall, the prognostic importance of MIB-1 index, p53-expession and tumour size was analysed. Multivariate analysis
identified two metastatic risk factors: increasing tumour size and MIB-1 >9%. The 5-year metastasis-free survival-rate for patients with tumour
size ≤5 cm + MIB-1 <10% was 0.83 (95% confidence interval (CI) 0.64–0.92) compared to 0.31 (95% CI 0.11–0.53) in cases with tumour size
>5 cm + MIB-1 ³10%. Our study shows that metastatic disease in synovial sarcoma is closely related to MIB-1 index. Using our model based
on tumour size and MIB-1 index, cases with good and poor prognosis can easily be discriminated. Therefore our model can be used to identify
patients who should be considered for adjuvant chemotherapy.
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Patients
The study was based on 104 patients diagnosed with synovial
sarcoma of the extremities or trunk wall between 1986 and 1994
(Skytting et al, submitted). Eighteen patients were excluded
because tumour material was not available, leaving 86 patients for
study.
The histopathological criteria for synovial sarcoma were those
of Enzinger and Weiss (Enzinger and Weiss, 1995). The SSG-
pathology-board, a selected group of pathologists from the partici-
pating centres, re-examined all available original slides from the
primary tumours without knowledge of the clinical course. In
selected cases new slides, immunohistochemical stainings or
RT-PCR (for detection of SYT-SSX hybrid products) were
performed for final diagnosis.
Medical records were reviewed in all cases to verify and
complete reported clinical data. There were 47 males and 39
females with a median age of 39 (6–81) years. Eight tumours were
located on the trunk wall, 41 in the proximal part of the extremities
(shoulder, upper arm, elbow, groin, gluteus, thigh and knee) and
37 in the distal part (lower arm, hand, lower leg and foot). The
median tumour size was 5 (1–20) cm. All tumours were high-
grade lesions (Grade III and Grade IV) on a 4-grade scale (Broders
and Hargrave, 1939; Angervall et al, 1986) except for one (Grade
II). In 34 patients, the final surgical margin was intralesional or
marginal, and in 52 wide or compartmental. None had preopera-
tive radiotherapy but 20 were treated postoperatively due to an
intralesional or marginal surgical margin. Four patients, three
children and one young adult, had adjuvant chemotherapy for
primary tumour. There was no systemic bias regarding post-
operative treatment and these markers.
No patient was lost to follow-up. The median follow-up for
survivors (n = 53) was 6 years (2–11) years. Thirty-one patients
(36%) developed metastases at a median of 1.5 years. The most
common site was the lungs.
Immunohistochemical examinations
All original haematoxylin and eosin-stained slides were re-exam-
ined and matched to the corresponding paraffin-embedded tissue
blocks. One representative block per tumour was selected for
immunostaining. Immunostaining was performed according to the
standard ABC-technique (Elite Standard Kit. Cat. PK-6100;
Vector, Burlingame, CA, USA). Paraffin sections were deparaf-
finized, rehydrated and pretreated. Antigen retrieval was
performed by immersing the specimens for 10 min in a citrate
buffer at pH 6 and heating in a microwave oven (700 W) for
10 min. After rinsing, the endogenous peroxidase activity was
blocked by hydrogen peroxide dissolved in methanol (3%
hydrogen peroxide to methanol, 1:5 by volume) for 30 min. The
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Figure 1 Photomicrographs of two synovial sarcoma cases studied using immunohistochemical staining with MIB1 antibody. Low proliferating activity: MIB-1
index = 0–9% (A). High proliferating activity: MIB-1 index >9% (B)sections were then rinsed and incubated with blocking serum
(normal horse serum) for 20 min and later incubated with primary
antibodies: anti-Ki-67 (MIB-1; Immunotech, Marseille, France)
1:50 and anti P-53 (DO-1, SDS; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) 1:100. All incubations were performed overnight
at 8°C. Following the ABC-complex, a biotinylated antimouse
immunoglobulin G was used as a secondary antibody. The
peroxidase reaction was developed using 3,3-diaminobenzidine
(diaminobenzidine tetrahydrochloride, 0.6 mg ml–1 with 0.03%
hydrogen peroxide) for 6 min. Haematoxylin was used as the
nuclear counterstain. Tris–phosphate-buffered saline (pH 7.6) was
used for rinsing between the steps. The staining was checked with
negative and positive controls.
A semiquantitative score was employed to assess the percentage
of cells that were positively stained regardless of staining intensity.
The percentage of MIB-1- and p53-positive cells per 10 high
power field (´ 250) were graded as follows: 0–1%, 2–9%,
10–24%, 25–49%, 50–74% and 75–100%.
All the immunohistochemically stained slides (which were
coded) were analysed microscopically independently by BTS and
OL without knowledge of the clinical characteristics. There was
concurrence of assessment in 144 of 154 specimen and over- or
underestimation of one score grade in ten. A consensus was
reached for these ten cases. In each case more than 1000 cells were
analysed.
Statistics
Metastases-free survival was analysed multivariately according
to Cox’s regression techniques supplemented with univariate
comparisons using the log-rank test and Kaplan–Meier survival
estimates (Kalbfleisch and Prentice, 1980).
RESULTS
MIB-1 and p53
Proliferation index was assessed by the MIB-1 antibody in 84 of
86 patients. Nuclear over-expression of p53 was determined in 70
of 86 patients. All of the material could not be stained for both
MIB-1 and p53 due to lack of tumour specimen. The distribution
of MIB-1-labelled nuclei among the 84 cases was: 0–1%, 13;
2–9%, 33; 10–24%, 22; 25–49%, 14; 50–74%, 1; 75–100%, 1. A
MIB-1 index of 10% or more was considered highly proliferative
(Figure 1). The p53 distribution was: 0–1%, 41; 2–9%, 6; 10–24%,
4; 25–49%, 11; 50–74%, 8. Specimens were at least 25% of the
nuclei stained positive for p53 were regarded as carrying p53
mutations in close conformity with other studies (Drobnjak et al,
1994).
Ki-67 in synovial sarcoma 1811
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Figure 2 Kaplan–Meier estimates for metastasis-free survival among
84 synovial sarcoma patients based on low (0–9%) n = 46 and high (>9%)
n = 38 proliferative MIB-1 index, P = 0.007 (log-rank test)
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Figure 3 Kaplan–Meier estimates for metastasis-free survival among 82
synovial sarcoma patients based tumour size ≤5 cm n = 49 and tumour size
>5 cm n = 33, P = 0.003 (log-rank test) (tumour size missing in four patients)
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Figure 4 Kaplan–Meier estimates for metastasis-free survival among 70
synovial sarcoma patients based on low (0–24%) n = 51 and high (>24%)
n = 19 p53, P = 0.007 (log rank test)
Table 1 Metastasis-free survival among 80 synovial sarcoma patients with
respect to MIB-1 index and tumour size according to Cox’s proportional
hazard model
Criteria Hazard ratio 95% Confidence
interval P-value
Tumour size 1–3 cm (Reference) – –
Tumour size 4–5 cm 3.9 0.86–18 0.08
Tumour size 6–20 cm 7.1 1.6–31 0.009
MIB-1 ³10% 2.2 1.0–4.6 0.04In 38 out of 84 patients the MIB-1 index was ³10%. The
staining pattern was generally evenly distributed throughout the
specimen and a clear-cut labelling of the tumour cells was
achieved. However, three slides in the low-proliferative group
stained unevenly, suggesting two or more cell-clones in the same
specimen. Two out of three of these patients developed metastases
(data not shown). There was a significant difference in the meta-
stasis-free survival rate for patients with a MIB-1 index ³10%
versus patients with a low index (log-rank P-value = 0.007)
(Figure 2). Twenty-one out of 38 patients developed metastases in
the highly proliferative group and only 12 out of 46 in the low-
proliferative group. A significant difference regarding metastasis-
free survival for patients with tumour size ≤5 cm and >5 cm was
also obvious (log-rank P-value = 0.003) (Figure 3).
No significant difference in metastasis-free survival was
detected for patients staining highly positive for p53 versus those
who did not (log-rank P-value = 0.63) (Figure 4). Seven out of
19 patients developed metastases in the group where p53 was
over expressed versus 19 of 51 where it was not.
Multivariate analysis
Tumour size has been introduced as a strong prognostic marker for
metastasis-free survival in synovial sarcoma (Choong et al, 1994;
Skytting et al, submitted). Tumour size was available for all but
four patients. We decided to recode tumour size as a categorical
covariate with three levels: 1–3, 4–5 and 6–20 cm respectively.
The categorization was used since the log hazard did not appear to
increase linearly with tumour size. Both tumour size (1–3, 4–5,
6–20 cm) and MIB-1 index were entered in a multivariate Cox
regression analysis for metastasis-free survival (Table 1).
Although larger tumours were slightly more likely to have MIB-1
index >9% both factors gave a significant contribution to the
model.
Figure 5 illustrates metastasis-free survival probabilities for
patients with tumour size at most 5 cm and MIB-1 less than 10%
compared to patients with tumour size more than 5 cm and MIB-1
above 9%. As shown, 5-year survival rate among the 30 patients
with small and low-proliferative tumours was as high as 0.83 (95%
CI 0.64–0.92), whereas it was only 0.31 (95% CI 0.11–0.53)
among the 18 with large and highly proliferative synovial
sarcomas.
DISCUSSION
Our study shows that MIB-1 index and tumour size are strongly
related to metastasis-free survival in primary synovial sarcomas.
Prognosis for synovial sarcomas and other STSs has so far been
based on a clinical and histopathological staging systems built up by
histological grade, tumour size and tumour spread. However, a
majority of synovial sarcomas are considered to be high-grade
lesions and in our material only one tumour was of low grade.
Furthermore, lack of concrete criteria for grading, different grading
systems and variable interobserver reproducibility contributes to
subjective interpretations (Coindre et al, 1986). In contrast, MIB-1
index and tumour size can be assessed objectively.
The monoclonal antibody Ki-67 exclusively reacts with a
protein (Ki-67) expressed only during the proliferating phase of
the cell cycle (late G1, G2, S and mitosis) (Gerdes et al, 1984). In
a number of publications Ki-67 has proven to be a reliable marker
for measuring cell growth in human neoplasmas (Brown et al,
1990). However, Ki-67 could only be applied on fresh tissue since
the antigen which it detects is denaturated by tissue fixation. With
the introduction of the MIB-1 antibody, a true Ki-67 equivalent,
and a new antigen retrieval technique with the use of microwaves
(Shi et al, 1991), immunostaining of formalin-fixed paraffin-
embedded (FFPE) material was possible with a high repro-
ducibility, equalling results obtained in fresh material (Gerdes
et al, 1992). A close correlation was found between the FFPE
material stained with MIB-1 and parallel fresh tissue stained with
Ki-67 (Cattoretti et al, 1992).
Previous results regarding the prognostic value of high levels of
Ki-67 or MIB-1 in STS varies; in angiosarcoma an association was
seen with poor prognosis (Meis-Kindblom et al, 1998) but this
observation was not repeated in a material of MFH (Zehr et al,
1990). Various results have been reported from mixed series,
usually non-significant in multivariate analysis except in Heslin’s
study of high-grade STS (Heslin et al, 1998). Since, only a few
histotype-specific studies regarding the prognostic value of Ki-67
have been published and there are reasons to believe that the
expression level differs from histotype, the prognostic significance
of Ki-67 might differ between different STS entities.
The cut-off values for MIB-1 index varies a lot throughout the
literature, probably depending on the tissue material observed and
possibly by the evaluation (median value/area of greatest density
of staining). For sarcomas a cut-off value in the range of 10%
(Choong et al, 1995) to 40% (Levine et al, 1997) has been utilized.
Following Choong and co-workers, we divided the material into
two groups of approximately equal sizes, based on the employed
semiquantitative score. A cut-off value of MIB <10% defined a
group with better metastasis-free survival rates compared to the
group with MIB ³10% (log-rank P-value = 0.007). As indicated
by our results it is possible that the presence of highly proliferating
cell clones among tumours in the low-proliferative group may
predict a worse prognosis. However, our material was too small
(only three cases) to give a conclusive answer to this question.
Image analysis technology has been used for the assessment of
Ki-67 staining partly to reduce intraobserver variability (Zehr et al,
1990). However, with a clear cut staining pattern for positive
nuclei, typically for MIB-1, we did not experience difficulties in
scoring the specimens manually.
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Figure 5 Kaplan–Meier estimates for metastasis-free survival in a low-risk
group n = 30 (tumour size ≤5 cm and MIB-1 <10) versus a high-risk group
n = 18 (tumour size >5 and MIB-1 ³10), P = 0.007 (log-rank test)Mutations of TP-53 and alterations in p53 protein expression,
has been described to occur in STS (Drobnjak et al, 1994). They
found in a mixed series of 174 patients with fresh frozen materials
of STS, a significantly reduced over all survival among patients
with p53 nuclear over-expression >20%. However, when only
high-grade lesions were taken into account, the difference was
not significant. Our study, based on paraffin-embedded tissues,
revealed nuclear overexpression in 19 of 70 tumours (27%) which
is close to what Drobnjak reported (Drobnjak et al, 1994).
However, we could not detect a difference in metastasis-free
survival between patients staining for less than 25% for p53 and
those who did not. Recently, the mdm2 gene responsible for
producing a protein that binds to p53 and eliminates its ability to
function as a transcription factor, has been shown to be amplified
in STS, resulting in an inactivation of wild-type p53. High levels
of Mdm2 has also been associated with poor survival especially
with an over-expression of p53 in the same tumour (Cordon-Cardo
et al, 1994). However, since the Mdm2 protein was not assessed
in this study the clinical significance can not be evaluated.
Evaluation regarding prognostic relevance in STS of different p53
antibodies revealed a positive marker frequency of 36–63% (Wurl
et al, 1997). The antibody, DO-1 that we used came out on top in
this study, indicating the right choice.
In conclusion, this study identifies a high-risk group of patients
with MIB-1 index ³10%, and tumour size >5 cm in primary
synovial sarcoma. Prognostication with magnetic resonance
imaging (MRI) for assessment of tumour size and core needle
biopsy for MIB-1 index would make it possible to identify high-
risk patients, before surgery, who can be considered for adjuvant
chemotherapy, and on the contrary identify low-risk patients who
should be managed by local treatment only. To the best of our
knowledge, the present study is the first describing MIB-1 index
to be a prognostic marker for metastasis-free survival in a well-
defined STS entity.
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